Loading...

FOLD AMICUS THERAPEUTICS INC Company Mergers 8-K Filing

MCS

FLD

AMICUS THERAPEUTICS INC

(FOLD)

2026 8-K

Merger Approved

Financial Results Announced

Acquisition Update

Merger Announcement

Financial Results Update

Financial Statements

Financial Statements

Asset Acquisitions

Earnings Report

Earnings Update

Earnings Update

Earnings Update

Quantitative Data

Quantitative Data

Quantitative Data

Financial Performance Data

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Other Special Situation

Quantitative Data

Quantitative Data

Filing with Quantitative Data

Quantitative Data

Filing with Quantitative Data

Financial Performance Data

External Links:

Amicus Therapeutics, Inc. reports it had approximately $294 million in cash and an estimated $634 million in product revenues for the year ended December 31, 2025, as part of the acquisition proposal by BioMarin Pharmaceutical Inc. dated January 26, 2026.

AI Assistant

AMICUS THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.